Search SciPol

Brought to you by

Developments

The latest developments around the fields of

  • Energy
  • Genetics/Genomics
  • Nanotechnology
  • Neuroscience
  • Robotics/AI

Pre-Existing Conditions Protection Act of 2017 (HR 1121, 115th Congress)

  • Government
  • Elected Body
  • Genetics/Genomics
  • Neuroscience

Original Development Brief – In the event the Patient Protection and Affordable Care Act is repealed: prohibits the application of health insurance exclusions based on pre-existing conditions, guarantees availability of health insurance for every employer and individual applying for coverage, and prohibits health insurance discrimination based on health status and health status-related factors, including genetic information.

Updated last July 28, 2017
for the 02/16/2017 version of HR 1121.

Individual’s Right Under HIPAA to Access their Health Information (HHS Guidance)

  • Government
  • Agency
  • Genetics/Genomics
  • Neuroscience

Original Development Brief – Provides individuals with a legal, enforceable right to see and receive copies, upon request, of the information in their medical and other health records maintained by their health care providers and health plans.

Updated last July 12, 2017
for the 01/07/2016 guidance.

National Defense Authorization Act for Fiscal Year 2018 (HR 2810 / S 1519, 115th Congress)

  • Government
  • Elected Body
  • Genetics/Genomics
  • Neuroscience
  • Robotics/AI

Authorizes appropriations for fiscal year 2018 for military activities of the Department of Defense and for military construction; establishes certain requirements and programs related to traumatic brain injury, post-traumatic stress disorder, chronic traumatic encephalopathy, artificial intelligence, drones, and biological engineering / genetic enhancement.

Updated last July 7, 2017
for the 07/06/2017 version of HR 2810.

FDA 2017 Discussion Paper on Laboratory Developed Tests

  • Government
  • Agency
  • Genetics/Genomics
  • Neuroscience

Original Development Brief – Proposes future regulatory oversight on LDTs, including a risk-based, phased-in approach, and amends key provisions of the 2014 draft guidance.

Updated last May 23, 2017
for the 01/13/2017 Discussion Paper.

Pages